A pharmacist called Lawrence LaBenne was observing something unsettling somewhere in a supermarket in Pennsylvania. The business offered a prescription savings program, which allows clients to sign up for a discount card and pay less for common drugs. The savings were genuine. They were utilized by people. However, the pharmacy was invoicing the government at the higher, non-discounted price when it filed claims with Medicare and Medicaid. not the actual cost that customers were paying.
In a nutshell, the distinction was profit, and LaBenne thought it was unlawful. In 2018, he brought a lawsuit. After eight years, the Department of Justice announced a $40 million settlement with Ahold Delhaize USA, a Dutch-owned grocery chain with pharmacies located throughout the US East Coast.
Since the claimed scheme’s mechanics rely on a particular term with a particular legal weight, it is important to comprehend them thoroughly. The “usual and customary” pricing is used by federal healthcare programs, such as Medicare Part D, Medicaid, and the military’s TRICARE program, to determine how much they will reimburse a pharmacy. It serves as a ceiling.
The government won’t pay more than ten dollars if a drugstore charges the majority of its consumers 10 dollars for a medication. Ahold Delhaize is accused of charging registered savings program members discounted prices at its pharmacies under the names Giant, Hannaford, Stop & Shop, and Food Lion, but reporting the higher, regular costs to the government when billing. The claim never included the discounted rate. In essence, the government was covering the cost of a transaction that had not really taken place.
There is no acknowledgement of misconduct in the Ahold Delhaize DOJ deal. As is customary in civil False Claims Act proceedings, the corporation settled the issue without admitting that it had done anything wrong, which usually leaves a certain amount of uncertainty in the air. Reporters were directed to the DOJ press release by a spokeswoman.
The payment was said to settle “allegations.” Large pharmacy operations rely on sophisticated billing software, and it’s not always clear if a widespread reporting error indicates intent or carelessness, so it’s possible that compliance issues rather than intentional fraud caused the pricing disparities. However, it’s also feasible that someone in the chain had a thorough understanding of the economics. As long as the parties consent to a settlement, courts are not required to decide which.
The settlement does validate the authority of the legislation that enabled it. A clause in the False Claims Act, which was first enacted during the Civil War to prevent fraud by government suppliers, permits private individuals to bring legal action on behalf of the government—a process known as the qui tam mechanism.
The whistleblower is paid if the case is successful. LaBenne will receive around $6.1 million from the government portion of the settlement, which is significant as a signal as well as compensation. Before his case was resolved, it remained on the court for eight years. It’s a lengthy wait. Additionally, it is not exceptionally lengthy by the standards of healthcare fraud cases. These instances have audit trails from thousands of prescription claims in several jurisdictions, making them logistically challenging.
Ahold Delhaize’s overall financial situation is more intricate than just the settlement. As it modifies its pharmacy pricing policies moving forward, the company, which was rated eleventh on Progressive Grocer’s 2026 list of top North American food retailers, has estimated a $450 million decline in comparable sales for 2026.
That number is the result of the company bringing its pricing into compliance with what it should have been reporting all along, which, in a roundabout way, validates the government’s fundamental claim regarding how the billing had previously operated. $40 million is the settlement amount. The transition to legal operations is ten times more expensive. It’s difficult to ignore that math.
For its part, the statement was exploited by the Justice Department to convey a message that went far beyond Ahold Delhaize. Acting Deputy Inspector General Scott Lampert underlined that HHS-OIG will “aggressively pursue” such behavior, while Assistant Attorney General Brett Shumate stated that the DOJ would prosecute “dishonest pharmacies.”
Accessible, practical, and ingrained in everyday life, pharmacies within supermarkets are becoming an increasingly important aspect of the American healthcare system. They have scalability thanks to the same business model that makes them valuable. Furthermore, in the context of healthcare billing, scale can transform a minor pricing disparity into a significant compliance issue before anyone is aware that it has been building up for years.
